Press Release: ECOG-ACRIN adds a late-breaking abstract to its ASH 2024 presentation line-up

Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of studies that aim to improve treatments for patients with lymphomas and acute leukemias at the 66th American Society of Hematology (ASH) Meeting & Exposition. The meeting is set to occur in San Diego, California, and virtually December 7 - 10, 2024.

Today, ASH announced that the ECOG-ACRIN trial EA4151 will be a late-breaking abstract at the meeting. Other highlights are the promising results from a phase 2 study (PrE0905) in patients with acute myeloid leukemia and the results of the phase 2 study EA4181 in patients with mantle cell lymphoma.

Details for the presentations are below, listed by type and date. Times are shown in Pacific Time.

Late-Breaking Abstract

• LBA-6 Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial
  Presenter: Timothy S. Fenske, MD (Medical College of Wisconsin)
  Oral: Abstract LBA-6 in Late-Breaking Abstracts Session
  Date and Time: Tuesday, December 10, 2024, 7:30 - 9:00 AM
  Location: San Diego Convention Center, Hall B

Trial Results

• Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Pre0905 Study in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
  Presenter: Selina M. Luger, MD (University of Pennsylvania)
  Oral: Abstract 221 in Session 617
  Date and Time: Saturday, December 7, 2:00 - 3:30 PM
  Presentation Time: 3:00 PM
  Location: Manchester Grand Hyatt San Diego, Seaport Ballrooms E-F-G-H

• Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181
  Presenter: Nina D. Wagner-Johnston, MD (Johns Hopkins University)
  Oral: Abstract 236 in Session 623
  Date and Time: Saturday, December 7, 2:00 - 3:30 PM
  Presentation Time: 2:15 PM
  Location: Marriott Marquis San Diego Marina, Grand Ballroom 11-13

New Data from the Practice-Changing E1910 Trial by ECOG-ACRIN

• Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
  Presenter: Nikolai A. Podoltsev, MD, PhD (Yale University)
  Poster: Abstract 4211 in Session 613
  Date and Time: Monday, December 9, 2024, 6:00 - 8:00 PM
  Location: San Diego Convention Center, Halls G-H
• Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
  Presenter: Michaela Liedtke, MD (Stanford University)
  Oral: Abstract 779 in Session 732
  Date and Time: Monday, December 9, 10:30 AM - 12:00 PM
  Presentation Time: 11:30 AM
  Location: San Diego Convention Center, Room 6A
• EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
  Presenter: Carolin S. Escherich, MD (St. Jude Children’s Research Hospital)
  Oral: Abstract 830 in Session 605
  Date and Time: Monday, December 9, 2:45 - 4:15 PM
  Presentation Time: 3:00 PM
  Location: San Diego Convention Center, Ballroom 20 C-D

Other New Data from ECOG-ACRIN Trials

• PKCδ-Mediated Phosphorylation of CD25 Initiates Feedback Control of Oncogenic Tyrosine Kinases in Acute Lymphoblastic Leukemia
  Presenter: Ruifeng Sun, BS (Yale University)
  Oral: Abstract 632 in Session 614
  Date and Time: Sunday, December 8, 4:30 - 6:00 PM
  Presentation Time: 4:45 PM
  Location: Marriott Marquis San Diego Marina, Grand Ballrooms 5-6

• Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)
  Presenter: Christopher J. Forlenza, MD (Memorial Sloan Kettering Cancer Center)
  Poster: Abstract 4427 in Session 624
  Date and Time: Monday, December 9, 2024, 6:00 - 8:00 PM
  Location: San Diego Convention Center, Halls G-H

Trial in Progress

• A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02
  Presenter: Jessica K. Altman, MD (Northwestern University)
  Poster: Abstract 2907.1 in Session 617
  Date and Time: Sunday, December 8, 6:00 - 8:00 PM
  Location: San Diego Convention Center, Halls G-H

Presenters are available for media interviews under the ASH Meeting Embargo Policy. To schedule an interview, send an email to Diane Dragaud, Director of Communications, at communications@ecog-acrin.org.

About ECOG-ACRIN

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a membership-based scientific organization known for advancing precision medicine and biomarker research through its leadership of major national clinical trials that integrate cutting-edge genomic approaches. Nearly 21,000 member researchers and advocates from approximately 1,400 cancer centers and community hospitals collaborate across ECOG-ACRIN’s nearly 40 scientific committees to design studies spanning the cancer care spectrum, from early detection to management of advanced disease. ECOG-ACRIN is funded primarily by the National Cancer Institute (NCI), part of the National Institutes of Health, through the National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP). To learn more, visit www.ecog-acrin.org and follow us on X/Twitter @EAonc, Facebook, LinkedIn, YouTube, and Instagram.

About PrECOG

PrECOG, LLC is a cancer research organization that designs and conducts innovative oncology studies through industry partnerships and research networks. The central focus of PrECOG is to conduct trials that align with the overall scientific mission and research goals of ECOG-ACRIN. To learn more, visit www.precogllc.org and follow us on X/Twitter @PrECOGonc, Facebook, and LinkedIn.